Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure

European Heart Journal

Volumn 34, Issue 1, 2013, Pages 57-67

  Erdmann, Erland ^a   Semigran, Marc J ^b   Nieminen, Markku S ^c   Gheorghiade, Mihai ^d   Agrawal, Rahul ^e   Mitrovic, Veselin ^f   Mebazaa, Alexandre ^g,h,i  

^a UNIVERSITY OF COLOGNE   (Germany)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d NORTHWESTERN UNIVERSITY   (United States)

^e BAYER PHARMA AG   (Germany)

^f KERCKHOFF HEART CENTER   (Germany)

^g HÔPITAL LARIBOISIÈRE   (France)

^h UNIVERSITÉ PARIS DESCARTES   (France)

ⁱ AP HP Saint Louis and Lariboisière University Hospitals   (France)

Author keywords

Cinaciguat; Clinical trial, phase 2; Haemodynamics; Heart failure; Soluble guanylyl cyclase; Vasodilation

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CINACIGUAT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; LEVOSIMENDAN; PLACEBO;

ACUTE HEART FAILURE; ADULT; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; FEMALE; HEART HEMODYNAMICS; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HEART RIGHT ATRIUM PRESSURE; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MORTALITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC VASCULAR RESISTANCE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ACUTE DISEASE; BENZOATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EARLY TERMINATION OF CLINICAL TRIALS; FEMALE; GLOMERULAR FILTRATION RATE; GUANYLATE CYCLASE-ACTIVATING PROTEINS; HEART FAILURE; HEMODYNAMICS; HUMANS; HYPOTENSION; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; TACHYCARDIA, VENTRICULAR; TREATMENT OUTCOME;

EID: 84872002780     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehs196     Document Type: Article

References (27)

1. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K, Vahanian A, Camm J, De Caterina R, Dean V, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388-2442.
2. Onwuanyi A, Taylor M. Acute decompensated heart failure: pathophysiology and treatment. Am J Cardiol 2007;99:25D-30D.
3. Allen LA, O'Connor CM. Management of acute decompensated heart failure. CMAJ 2007;176:797-805. (Pubitemid 46456378)
4. Chung P, Hermann L. Acute decompensated heart failure: formulating an evidence-based approach to diagnosis and treatment (part I). Mt Sinai J Med 2006;73:506-515.
5. Alla F, Zannad F, Filippatos G. Epidemiology of acute heart failure syndromes. Heart Fail Rev 2007;12:91-95. (Pubitemid 46916953)
6. Munzel T, Daiber A, Mulsch A. Explaining the phenomenon of nitrate tolerance. Circ Res 2005;97:618-628. (Pubitemid 41416330)
7. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007;87:315-424. (Pubitemid 46217686)
8. Evgenov OV, Pacher P, Schmidt PM, Hasko G, Schmidt HH, Stasch JP. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 2006;5:755-768. (Pubitemid 44323702)
9. Tamargo J, Duarte J, Caballero R, Delpon E. Cinaciguat, a soluble guanylate cyclase activator for the potential treatment of acute heart failure. Curr Opin Investig Drugs 2010;11:1039-1047.
10. Martin F, Baskaran P, Ma X, Dunten PW, Schaefer M, Stasch JP, Beuve A, van den Akker F. Structure of cinaciguat (BAY 58-2667) bound to nostoc H-NOX domain reveals insights into heme-mimetic activation of the soluble guanylyl cyclase. J Biol Chem 2010;285:22651-22657.
11. Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Lapp H, Stasch JP, Burnett JC Jr. Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure. Hypertension 2007;49:1128-1133. (Pubitemid 351664312)
12. Jones ES, Kemp-Harper B, Stasch JP, Schmidt H, Widdop RE. Cardioprotective effects in aged spontaneously hypertensive rats due to chronic stimulation/activation of sGC without hypotension. BMC Pharmacol 2009;9 (Suppl 1):29.
13. Lapp H, Mitrovic V, Franz N, Heuer H, Buerke M, Wolfertz J, Mueck W, Unger S, Wensing G, Frey R. Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Circulation 2009;119: 2781-2788.
14. Nieminen MS, Bohm M, Cowie MR, Drexler H, Filippatos GS, Jondeau G, Hasin Y, Lopez-Sendon J, Mebazaa A, Metra M, Rhodes A, Swedberg K, Priori SG, Garcia MA, Blanc JJ, Budaj A, Dean V, Deckers J, Burgos EF, Lekakis J, Lindahl B, Mazzotta G, Morais J, Oto A, Smiseth OA, Dickstein K, Albuquerque A, Conthe P, Crespo-Leiro M, Ferrari R, Follath F, Gavazzi A, Janssens U, Komajda M, Moreno R, Singer M, Singh S, Tendera M, Thygesen K. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:384-416. (Pubitemid 40283098)
15. Frey R, Mück W, Unger S, Artmeier-Brandt U, Weimann G, Wensing G. Pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in healthy male volunteers. J Clin Pharmacol 2008;48:1400-1410.
16. Colucci WS. Nesiritide for the treatment of decompensated heart failure. J Card Fail 2001;7:92-100. (Pubitemid 32285194)
17. Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, Wagoner LE, Givertz MM, Liang CS, Neibaur M, Haught WH, LeJemtel TH. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000;343:246-253. (Pubitemid 30490392)
18. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkar R, Padley RJ, Poder P, Kivikko M. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007;297:1883-1891. (Pubitemid 46707842)
19. Cuffe MS, Califf RM, Adams KF Jr, Benza R, Bourge R, Colucci WS, Massie BM, O'Connor CM, Pina I, Quigg R, Silver MA, Gheorghiade M. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002;287:1541-1547. (Pubitemid 34269999)
20. McMurray JJ, Teerlink JR, Cotter G, Bourge RC, Cleland JG, Jondeau G, Krum H, Metra M, O'Connor CM, Parker JD, Torre-Amione G, van Veldhuisen DJ, Lewsey J, Frey A, Rainisio M, Kobrin I. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 2007;298:2009-2019. (Pubitemid 350074798)
21. Mebazaa A, Parissis J, Porcher R, Gayat E, Nikolaou M, Boas FV, Delgado JF, Follath F. Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensity scoring methods. Intensive Care Med 2011;37:290-301.
22. Peacock WF, De Marco T, Fonarow GC, Diercks D, Wynne J, Apple FS, Wu AH. Cardiac troponin and outcome in acute heart failure. N Engl J Med 2008; 358:2117-2126. (Pubitemid 351679598)
23. You JJ, Austin PC, Alter DA, Ko DT, Tu JV. Relation between cardiac troponin I and mortality in acute decompensated heart failure. Am Heart J 2007; 153:462-470. (Pubitemid 46440690)
24. Roongsritong C, Warraich I, Bradley C. Common causes of troponin elevations in the absence of acute myocardial infarction: incidence and clinical significance. Chest 2004;125:1877-1884. (Pubitemid 38648423)
25. Sweitzer NK, Lopatin M, Yancy CW, Mills RM, Stevenson LW. Comparison of clinical features and outcomes of patients hospitalized with heart failure and normal ejection fraction (. or¼55%) versus those with mildly reduced (40% to 55%) and moderately to severely reduced (, 40%) fractions. Am J Cardiol 2008;101:1151-1156.
26. Gheorghiade M, Filippatos G, Erdmann E, Ferrari R, Levy PD, Maggioni A, Nowack C, Mebazaa A. Treatment of acute decompensated heart failure with the soluble guanylate cyclase activator cinaciguat: The COMPOSE program: three randomized, controlled, phase IIb studies. J Card Fail 2011;17:971.
27. Benz K, Orth SR, Simonaviciene A, Linz W, Schindler U, Rutten H, Amann K. Blood pressure-independent effect of long-term treatment with the soluble heme-independent guanylyl cyclase activator HMR1766 on progression in a model of noninflammatory chronic renal damage. Kidney Blood Press Res 2007; 30:224-233. (Pubitemid 47076219)